Genmab Provided Earnings Guidance for Year 2022. For the year, company expects its revenue to be in the range of DKK 13,500 million DKK 14,500 million, an increase to the previous guidance of DKK 12,000 million DKK 13,000 million and expects operating profit to be in the range of DKK 5,100 million DKK 6,500 million, an increase to the previous guidance of DKK 3,800 million DKK 5,400 million, driven primarily by the items described above.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,954 DKK | +2.04% | -2.57% | -9.30% |
Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.30% | 18.15B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B | |
-24.71% | 8.24B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab Provides Earnings Guidance for Year 2022